Loading...
•
Jun 30, 2023
Bio-Techne Q4 2023 Earnings Report
Bio-Techne's Q4 2023 performance was marked by a 5% increase in organic revenue and strategic growth platform success.
Key Takeaways
Bio-Techne reported a 5% increase in organic revenue for Q4 2023, reaching $301.3 million. The company's Diagnostics and Genomics segment saw a 10% organic growth, driven by strong commercial execution. Strategic growth platforms like ExoDx prostate test and GMP proteins delivered record performance with revenue growth of 68% and 58%, respectively. Bio-Techne also finalized the acquisition of Lunaphore, enhancing its spatial biology franchise.
Organic revenue increased by 5% to $301.3 million.
GAAP EPS was $0.47, and adjusted EPS was $0.55.
Diagnostics and Genomics segment experienced 10% organic growth.
ExoDx prostate test and GMP proteins showed strong revenue growth of 68% and 58%, respectively.
Revenue by Segment
Forward Guidance
No specific forward guidance was provided in the press release.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...